SADR reporting triggers post-marketing safety actions by the FDA.

SADR reporting triggers post-marketing safety actions by the FDA.

• A. True
• B. False
• C. Only for antibiotics
• D. Only for devices

Answer: (A)

The key idea is that serious adverse drug reaction reports serve as a vital signal for ongoing safety monitoring after a product is on the market. When a SADR is reported to the FDA, regulators evaluate how serious the event is, whether it is potentially related to the drug, and how strong the signal is. If the assessment suggests a real safety concern, the FDA can take actions to protect patients, such as updating the product’s labeling with new warnings or precautions, adding contraindications, adjusting recommended use, implementing risk evaluation and mitigation strategies, issuing safety communications, or even removing the product from the market. This process applies broadly to drugs across all categories, not just antibiotics or devices, so those options don’t fit.

The key idea is that serious adverse drug reaction reports serve as a vital signal for ongoing safety monitoring after a product is on the market. When a SADR is reported to the FDA, regulators evaluate how serious the event is, whether it is potentially related to the drug, and how strong the signal is. If the assessment suggests a real safety concern, the FDA can take actions to protect patients, such as updating the product’s labeling with new warnings or precautions, adding contraindications, adjusting recommended use, implementing risk evaluation and mitigation strategies, issuing safety communications, or even removing the product from the market. This process applies broadly to drugs across all categories, not just antibiotics or devices, so those options don’t fit.